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INTRODUCTION AND OBJECTIVES 
 
Influenza A gutless vector:  new approach against lung cancer 
MATERIALS AND METHODS 
• In vitro experiments 
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 DISCUSSION AND CONCLUSION 
 
 
• Since there are no results, only conjectures can be made. Probably, gutless Influenza A vector with TK gene would be obtained, but the main problem of this 
whole procedure is that the efficiency is very low, which means that in order to achieve a good level of therapeutic virus, high input is required. Then, 
optimization is obligatory. In addition, counting the optimization time, this project was thought to be done in 3 years as a thesis project. 
 
• In conclusion, despite the fact that some modifications of the process have to be done, this work shows a first attempt in the development of  an Influenza 
A gutless vector that hopefully could be used as a complementary treatment against lung cancer in the future.  
 
 
• Lung cancer is the most common cause of cancer-related death in men and women worldwide. The actual treatments for this disease are chemotherapy, 
radiography and surgery; the main problem with them is that they are not always effective and can lead to bad secondary effects. Thus, there is an urgent 
need in finding an effective and harmless alternative for lung cancer therapeutics.  
 
• The aim of this project is to establish a different treatment against lung cancer, as a part of a final project report, based on one of the most promising new 
therapies nowadays: virotherapy. Although the use of engineered virus has been reported in the consulted literature before, no satisfactory results have 
been achieved. Thus, this work proposes the usage of a gutless engineered Influenza A/Aichi/2/68 H3N2, which has a natural tropism for lung, with the gene 
coding for the thymidine kinase protein to infect a culture of human lung malignant cells and test the killing rate in presence of ganciclovir in media culture.  
• Ex vivo experiments 
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• In order to see if the infection is efficient the killing ratio by ganciclovir (GCV) is tested. 
Also, to test whether there is a differences between normal and malignant  phenotypes, 
two cell lines are used.  
• Level of formazan, product from tetrazolium salts reduction, in media culture is required 
for this toxicity assay since it is only present in living, metabolically active cells. 
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• In this case, the 5´ and 3´UTRs are eliminated in each 
amplicon due to the need to obtain viral genes 
without the possibilities of being packed in the viral 
capsids that they can form.  
Construction of 
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Digestion with BspBI and BamH1 + Ligation 
• First, it is needed to do an amplification by 
PCR of the thymidine kinase gene (TK); 
adding two restriction sites for BspHI and 
BamHI as shown below.  
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• Second, another RT-PCR for the virus 
Hemagglutinin 3 (HA) gene is performed. In 
this case, it is amplified the whole gene, with 
5´ and 3´UTRs. The result is shown below. 
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• Two types of 
molecules are 
synthetized 
after ligation:  
1. By RNA pol II:  mRNA, 
2. By RNA pol I: (-) ssRNA (only TK 
plasmid has the UTRs necessary 
to be packed). 
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METHODOLOGY 
• As a basis for the development of this work, many information sources such as paper reviews, patents, books, on-line official web pages, on-line catalogue 
were consulted. Also, an interview with a specialist in virus-mediated gene therapy from the Institut Català d’Oncologia (ICO).  
